文献速递耳科与耳神经

中国成人单侧人工耳蜗植入的成本效果分析

Cost-Effectiveness of Unilateral Cochlear Implants in Chinese Adults: Decision Analytical Modeling.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-09-14

本研究采用Markov模型,从中国医疗系统角度评估单侧人工耳蜗植入(UCI)对比助听器(HA)治疗成人重度或极重度感音神经性听力损失的成本效果。结果显示,UCI增量成本为216,414.37元,增量效用为3.34 QALYs,ICER为64,794.72元/QALY,低于WHO推荐的1-3倍人均GDP阈值,表明UCI具有成本效果。

要点

  • UCI较HA的ICER为64,794.72元/QALY,低于WHO推荐阈值。
  • 增量成本216,414.37元,增量效用3.34 QALYs。
  • 敏感性分析和年龄情景分析显示结果稳健。

核心结论

  • 单侧人工耳蜗植入对中国成人重度或极重度感音神经性听力损失患者是具有成本效果的干预措施。

研究设计与样本

  • 成本效果分析,采用Markov模型,从中国医疗系统角度,基于患者终身时间范围,成本和结果按每年5%贴现。
  • 数据来自中国北、东、南、西部的六家三级医院,这些医院为国家区域医疗中心或WHO防聋合作中心。

主要发现

  • UCI相比HA的增量成本为216,414.37元,增量效用为3.34 QALYs。
  • ICER为64,794.72元/QALY,低于WHO推荐的1-3倍人均GDP阈值(中国2022年人均GDP范围=85,698-257,094元)。
  • 敏感性分析和基于年龄的情景分析表明结果稳定性良好。

关键数值与推荐

  • ICER为64,794.72元/QALY,处于人均GDP的47%至88%之间(研究估计为77%)。

临床怎么用

  • 结果可为中国成人重度听力损失患者引入单侧人工耳蜗植入干预提供卫生经济学依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to evaluate the cost-effectiveness of unilateral cochlear implants (UCIs) in Chinese adults with severe or profound sensorineural hearing loss, which helps to inform the introduction of a new intervention for underserved adult patients with severe hearing loss. STUDY DESIGN: Cost-effectiveness analysis. SETTING: Six tertiary hospitals located in north, east, south, and west China, designated as National Regional Medical Centers or WHO Collaborating Centers for the Prevention of Deafness. METHODS: Using a Markov model, we conducted cost effectiveness analysis over the patient's lifetime and from the perspective of the Chinese healthcare system. Costs and outcomes are discounted by 5% annually. Compared with the control measures of hearing aids (HAs), interventions for UCIs include surgery, rehabilitation, regular maintenance, and periodic replacements. RESULTS: The incremental cost of UCIs versus HAs was 216,414.37 CNY, which was accompanied by an incremental utility value of 3.34 QALYs. Therefore, UCIs demonstrated superior cost-effectiveness compared with HAs. The incremental cost-effectiveness ratio (ICER) was 64,794.72 Chinese yuan (CNY)/quality-adjusted life years (QALY), indicating that the cost required to gain one additional QALY was 64,794.72 CNY. The ICER was below the World Health Organization-recommended threshold of 1 to 3 times the GDP per capita (China's 2022 GDP per capita range = 85,698-257,094 CNY) and falls within 47% to 88% of the per capita GDP (research estimates 77%). Sensitivity analyses and age-based scenario analyses indicated good stability of the results. CONCLUSIONS: UCIs are a cost-effective intervention for adults in China.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Wu D, Qiu Y, Xiao Y, et al. Cost-Effectiveness of Unilateral Cochlear Implants in Chinese Adults: Decision Analytical Modeling. Otolaryngol Head Neck Surg. 2026. PMID: 42735054. doi:10.1002/ohn.70427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。